Table. Resistance to specific antimicrobial drugs in Salmonella enterica serotype Newport from humans in France, 2000–2005*.
| Drug | % Resistant isolates |
|||||
|---|---|---|---|---|---|---|
| 2000 (n = 100) (N = 109) | 2001 (n = 124) (N = 134) | 2002 (n = 66) (N = 71) | 2003 (n = 126) (N = 138) | 2004 (n = 91) (N = 94) | 2005 (n = 78) (N = 80) | |
| Amoxicillin | 27 | 9.7 | 1.5 | 19.8 | 8.8 | 3.8 |
| Ceftriaxone/ceftazidime | 15 | 4 | 1.5 | 17.5 | 2.2 | 0 |
| Gentamicin | 4 | 1.6 | 0 | 1.6 | 2.2 | 0 |
| Nalidixic acid | 23 | 7.3 | 4.5 | 1.6 | 4.4 | 2.6 |
| Ciprofloxacin | 0 | 0 | 0 | 0 | 0 | 0 |
| Sulfonamides | 29 | 10.5 | 4.5 | 19.8 | 8.8 | 0 |
| Trimethoprim | 10 | 4 | 3 | 1.6 | 4.4 | 0 |
| Chloramphenicol | 25 | 9.7 | 1.5 | 15.9 | 8.8 | 0 |
| Tetracycline | 27 | 11.3 | 3 | 19 | 9.9 | 3.8 |
*n, no. of isolates studied; N, no. of isolates received at the French National Reference Centre for Salmonella (1 per patient).